Neoadjuvant mFOLFIRINOX Studied for Borderline Resectable PDAC
WEDNESDAY, Aug. 3, 2022 (HealthDay News) — For patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC), favorable overall survival was observed following treatment with eight cycles of neoadjuvant modified FOLFIRINOX (mFOLFIRINOX)…
Learn MoreNeoadjuvant mFOLFIRINOX Studied for Borderline Resectable PDAC
WEDNESDAY, Aug. 3, 2022 (HealthDay News) — For patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC), favorable overall survival was observed following treatment with eight cycles of neoadjuvant modified FOLFIRINOX (mFOLFIRINOX)…
Learn MoreHearing Loss, Tinnitus Common After Neurotoxic Chemo for Cancer
TUESDAY, Aug. 2, 2022 (HealthDay News) — Cancer survivors who received a platinum alone, a taxane alone, or a platinum- and taxane-containing regimen have similar rates of hearing loss and tinnitus, according to a study published online July 27 in BM…
Learn MoreKeytruda Extends Survival for Women With an Aggressive Breast Cancer
THURSDAY, July 21, 2022 (HealthDay News) — Adding the drug Keytruda to standard chemotherapy can extend the lives of some women with an aggressive form of breast cancer, a new study finds.The study involved women with advanced triple-negative breast …
Learn MoreAbortion Bans Could Put Lives of Cancer Patients in Jeopardy
TUESDAY, July 12, 2022 (HealthDay News) — The U.S. Supreme Court’s decision to overturn Roe v. Wade will limit cancer treatment options for pregnant women and put lives needlessly at risk, America’s leading cancer societies warn.About one in every 1,…
Learn More